Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea

Last updated: January 24, 2025
Sponsor: Wright State University
Overall Status: Active - Recruiting

Phase

2

Condition

Rosacea

Treatment

Amitriptyline

Vehicle

Imipramine

Clinical Study ID

NCT06312813
2023-296
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Fitzpatrick Skin Type I - IIII

  • Self-identified rosacea or no history of flushing/blushing for controls

  • Able to provide medical history and list of medications -- control subjects will notbe allowed to take medications that are known to be photosensitizers.

Exclusion

Exclusion Criteria:

  • Using imipramine, amitriptyline or any other tricyclic antidepressant (oral ortopical)

  • Using topical anti-inflammatory (within 1 week) or systemic agents (e.g. prednisone)

  • Large tattoos in the designated testing areas

  • Tanning bed use within last 3 months

  • Photodynamic Therapy or UCB treatments in past 3 months

  • Female Subjects: pregnant or nursing

Study Design

Total Participants: 48
Treatment Group(s): 3
Primary Treatment: Amitriptyline
Phase: 2
Study Start date:
February 27, 2024
Estimated Completion Date:
December 01, 2028

Connect with a study center

  • Wright State Physicians

    Fairborn, Ohio 45324
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.